ajmc.com/view/real-world-st...
« Collectively, the ability of IFNα to target the disease-initiating mutant clone and the emergence of safer, more easy-to-use, and longer acting Ropeg foretells a brilliant future in the field of MPN, as we now have a promising disease-modifying agent that could someday help eradicate this clonal disorder. In fact, studies have shown that IFNα induces complete molecular response in about 10–15% of the treated patients, and JAK2V617F mutation was rendered undetectable in a similar percentage of patients treated beyond 4 years in the PROUD/CONTI-PV study. Our clinical experience somehow echoes this finding, as two patients exposed to this agent for the longest duration (both more than 60 weeks) had drastically declined JAK2 mutant AB below 20% »